# Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

> **NCT02076997** · NA · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 23 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02076997
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-01
- **Primary completion:** 2017-05-30
- **Final completion:** 2019-05-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076997, "Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02076997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*